U.S. FDA Issues Warning Letter To Lupin Citing Manufacturing Deficiencies; Warns Products Will Not Be Approved Until Corrective Action

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.